Stanford Peng, MD, PhD

Virginia Mason Medical Center, Seattle, WA (At time of LRI grant, Dr. Peng was at Washington University in St. Louis)

2002 Cell Signaling

Dr. Peng was awarded an LRI grant to identify transcription factors that regulate the development of lupus-like autoimmunity in mice.

He used a sophisticated molecular technique called “DNA microarray” to compare the messenger RNA of transcription factors of immune system cells from mice with lupus with immune system cells from control mice.

Over the course of his grant, he ultimately identified a role for four new transcription-factor controlled pathways in the development of systemic autoimmunity. With numerous publications in high-profile journals, his discoveries have had a major impact on the field.

Dr. Peng turned established thinking around by showing that autoimmune diseases such as lupus may result from a malfunction in a particular gene (Foxj1) that under normal circumstances helps to restrain the immune system from attack.

In 2005, Dr. Peng and his colleagues reported identifying a related gene, Foxo3a, that defuses inflammatory arthritis, a painful complication in many people with lupus.

“Modifying the activity of Foxo3a may be a useful approach to treating people with inflammatory conditions caused by immune dysfunction, such as lupus,” said Dr. Peng.

Dr. Peng’s LRI work had an enormous impact on the field, generating 4 landmark papers with multiple citations in the peer-reviewed literature—over 400 in all.

In 2010, nearly a decade after receiving his LRI grant, Dr. Peng reported that he is still involved in lupus research—primarily via  clinical trials.

Read more about Dr. Peng’s discoveries

Select publications:

Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Jonsson H, Allen P, Peng SL. Nat Med. 2005 Jun;11(6):666-71. Epub 2005 May 15.

Restraint of B cell activation by Foxj1-mediated antagonism of NF-kappa B and IL-6. Lin L, Brody SL, Peng SL. J Immunol. 2005 Jul 15;175(2):951-8.

Interleukin-18 receptor signaling is not required for autoantibody production and end-organ disease in murine lupus. Lin L, Peng SL. Arthritis Rheum. 2005 52(3):984-6.

Modulation of Th1 activation and inflammation by the NF-kappaB repressor Foxj1. Lin L, Spoor MS, Gerth AJ, Brody SL, Peng SL. Science. 2004 303(5660):1017-20.

SH2D1A regulates T-dependent humoral autoimmunity. Hron JD, Caplan L, Gerth AJ, Schwartzberg PL, Peng SL. J Exp Med. 2004 200(2):261-6.

Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Lin L, Hron JD, Peng SL. Immunity. 2004 21(2):203-13.

Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. Lin L, Gerth AJ, Peng SL. J Exp Med. 2004 200(1):115-22.

Regulation of the symmetry and intensity of immune complex-mediated synovitis by nuclear factor of activated T cells. Gerth AJ, Pham CT, Peng SL. Arthritis Rheum. 2004 50(10):3392-5.

T-bet regulates T-independent IgG2a class switching. Gerth AJ, Lin L, Peng SL. Int Immunol. 2003 15(8):937-44.

Ongoing funding:

In 2004, Dr. Peng won a 1.75 million National Institutes of Health grant to continue the work begun in part with his LRI grant.

Rev. July 2010